Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Debt to Equity (2021 - 2026)

Axsome Therapeutics' Debt to Equity history spans 6 years, with the latest figure at $2.36 for Q1 2026.

  • On a quarterly basis, Debt to Equity fell 33.82% to $2.36 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.36, a 33.82% decrease, with the full-year FY2025 number at $1.45, down 54.35% from a year prior.
  • Debt to Equity hit $2.36 in Q1 2026 for Axsome Therapeutics, up from $1.45 in the prior quarter.
  • Over the last five years, Debt to Equity for AXSM hit a ceiling of $6.54 in Q2 2022 and a floor of $0.64 in Q3 2022.
  • Historically, Debt to Equity has averaged $2.06 across 5 years, with a median of $1.73 in 2025.
  • Biggest five-year swings in Debt to Equity: crashed 89.96% in 2023 and later soared 228.12% in 2024.
  • Tracing AXSM's Debt to Equity over 5 years: stood at $0.91 in 2022, then rose by 5.66% to $0.97 in 2023, then skyrocketed by 228.12% to $3.17 in 2024, then crashed by 54.35% to $1.45 in 2025, then surged by 63.32% to $2.36 in 2026.
  • Business Quant data shows Debt to Equity for AXSM at $2.36 in Q1 2026, $1.45 in Q4 2025, and $1.73 in Q3 2025.